Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R3ACT: Virus and Fungus Specific T-cells for Infections Post-Transplant
NCT02779439Phase 1Unknown
- Sponsor
- University of Sydney
- Start
- Jan 2013
- Primary completion
- Dec 2017
- Countries
- 1
01
Overview
Phase 1, open-label trial of virus-specific CTLs in cytomegalovirus infection (CMV), Epstein-Barr virus infection, adenovirus infection and 3 more, sponsored by University of Sydney. Primary endpoint: Infusion related safety at 1 week. Status: unknown.
02
Drugs
virus-specific CTLs
03
Conditions
cytomegalovirus infection (CMV)Epstein-Barr virus infectionadenovirus infectioninvasive fungal disease (IFD)aspergillosis
Beyond the preview
Go deeper on NCT02779439.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02779439.